Alterity Therapeutics Limited (FRA:PBN)

Market Cap	49.60M
Revenue (ttm)	3.04M
Net Income (ttm)	-6.78M
Shares Out	n/a
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,300
Open	0.0050
Previous Close	0.0035
Day's Range	0.0050 - 0.0050
52-Week Range	0.0015 - 0.0100
Beta	n/a
RSI	54.89
Earnings Date	Feb 25, 2026

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 9
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PBN

Financial Performance

In 2025, Alterity Therapeutics's revenue was 5.44 million, an increase of 35.32% compared to the previous year's 4.02 million. Losses were -12.15 million, -36.48% less than in 2024.

Financial numbers in AUD